(Q54969341)

14 June 2018

title

Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. (English)

1 reference

14 June 2018

1 reference

Y Ando

1

1 reference

14 June 2018

H Minami

2

1 reference

14 June 2018

H Saka

3

1 reference

14 June 2018

M Ando

4

1 reference

14 June 2018

S Sakai

5

1 reference

14 June 2018

K Shimokata

6

1 reference

14 June 2018

publication date

1 February 1996

1 reference

14 June 2018

number of pages

6

1 reference

Japanese Journal of Cancer Research

inferred from page(s)

published in

1 reference

14 June 2018

volume

87

1 reference

14 June 2018

page(s)

200-205

1 reference

14 June 2018

issue

2

1 reference

14 June 2018

Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Chronic etoposide administration: overview of clinical experience

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Estimation of variance for harmonic mean half-lives.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Etoposide (VP-16-213). Current status of an active anticancer drug

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921058

Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer

13 August 2018

1 reference

12 December 2020

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity

1 reference

12 December 2020

Variable bioavailability following repeated oral doses of etoposide

1 reference

12 December 2020

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide

1 reference

12 December 2020

Changes in the clearance of total and unbound etoposide in patients with liver dysfunction

1 reference

12 December 2020

Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer

1 reference

12 December 2020

10.1111/J.1349-7006.1996.TB03159.X

Identifiers

DOI

1 reference

14 June 2018

PMCID

5921058

1 reference

14 June 2018

PubMed ID

8609070

1 reference

14 June 2018